Joel Neal, MD, PhD
Publications
- A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. J Thorac Oncol. 2013; (2): e17-8
- A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. J Natl Compr Canc Netw. 2013; (4): 389-94
- Aflibercept in lung cancer. Expert Opin Biol Ther. 2013; (1): 115-20
- A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012; (10): 1602-8
- Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2012; (18): 2280-2
- First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics. 2012: 337-45
- Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; (17): 2046-54
- Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. J Thorac Oncol. 2012; (16 Suppl 5): S385-6
- Current management of small cell lung cancer. Clin Chest Med. 2011; (4): 853-63
- One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer. Clin Cancer Res. 2011; (4): 638-9
- Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer. J Thorac Oncol. 2011; (11 Suppl 4): S1797-8
- AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther. 2010; (4): 487-95
- Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol. 2010; (1-2): 36-44
- Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nat Rev Clin Oncol. 2010; (2): 71-2
- The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncol. 2010; (12): 1827-32
- A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J Biol Chem. 2003; (19): 17246-54
- Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells. Blood. 2003; (5): 1771-8
- Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells. J Biol Chem. 2002; (51): 49776-81
- Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. J Biol Chem. 2001; (5): 3666-73
- Regulation of the glucose:H+ symporter by metabolite-activated ATP-dependent phosphorylation of HPr in Lactobacillus brevis. J Bacteriol. 1994; (12): 3484-92
Help
Trial Administration